Context Therapeutics (CNTX) Operating Expenses (2020 - 2026)

Context Therapeutics has disclosed Operating Expenses across 7 years of filings, most recently posting $1.9 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $1.9 million, up 79.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.0 million (up 74.64% YoY), and the FY2025 annual result was $4.9 million, down 12.83% from the prior year.
• Operating Expenses came in at $1.9 million for Q1 2026 at Context Therapeutics, up from $1.4 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $6.9 million in Q4 2023 to a low of $922132.0 in Q4 2024.
• The 5-year median for Operating Expenses is $2.7 million (2022), against an average of $3.2 million.
• Across the five-year window, Operating Expenses soared 309.72% in 2022 and sank 86.7% in 2024, its largest moves.
• Context Therapeutics' Operating Expenses stood at $3.9 million in 2022, then surged by 78.58% to $6.9 million in 2023, then tumbled by 86.7% to $922132.0 in 2024, then jumped by 49.05% to $1.4 million in 2025, then soared by 38.58% to $1.9 million in 2026.
• The last three Operating Expenses figures came in at $1.9 million (Q1 2026), $1.4 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.